Bold claim: Rescheduling marijuana is not just a policy tweak—it’s a crossroads that could redefine how we address substance use in America. Here’s a clearer, beginner-friendly rewrite of the original piece, preserving all key facts while expanding a bit for context and understanding.
Republican Representative Mike Lawler of New York expressed strong caution on Monday about President Trump potentially reclassifying marijuana to a less restrictive category. He argued that changing marijuana’s classification would be inappropriate and not in the country’s best interest.
Lawler told NewsNation’s The Hill host Blake Burman, “I think rescheduling marijuana is wrong. The fact is, marijuana is a gateway drug. Most people who end up using hard substances start out on marijuana.” This reflects a long-standing concern some lawmakers voice about early exposure to cannabis potentially leading to more serious drug use later on.
Earlier that day, the president indicated he was considering reclassifying cannabis to a less dangerous Schedule. The Biden administration began efforts to move marijuana from Schedule I to Schedule III last year, but the process wasn’t completed before President Biden left office.
Lawler emphasized another point: the potency of cannabis has increased over time. He noted that the average concentration of THC, the primary psychoactive component in marijuana, has risen significantly—from about 5% in the 1990s to roughly 15–20% today, according to the Washington State Liquor and Cannabis Board. Higher THC levels are often associated with stronger effects and may influence risk profiles for users.
Under current U.S. drug scheduling, marijuana has been classified as a Schedule I substance since 1971. Schedule I means the drug is considered to have no accepted medical use and a high potential for abuse, a designation assigned by the Drug Enforcement Administration. In contrast, Schedule III drugs are viewed as having a moderate to low potential for dependence and include substances such as ketamine, certain anabolic steroids, and testosterone.
There are health considerations associated with long-term marijuana use. The National Institute on Drug Abuse points to links between extended cannabis use and various health concerns, including respiratory issues, mental health effects, gastrointestinal problems, and an increased risk of cancers in the head, neck, or throat region. The institute also notes that risk factors for marijuana addiction resemble those of other addictive substances, with starting at a younger age increasing the likelihood of developing a cannabis use disorder later in life.
Policy context remains mixed at the state level. As of now, 42 states plus Washington, D.C., have legalized medical marijuana, and 24 states allow recreational use.
In summary, Lawler argues against rescheduling marijuana, suggesting that doing so could complicate efforts to combat substance use disorders and may carry unintended consequences. He remains opposed to reclassification while acknowledging ongoing public health challenges related to substance use.
What do you think? Should marijuana be rescheduled to reflect changing potency and medical considerations, or should it stay in its current category? Share your thoughts and whether you agree with Lawler’s stance or see merit in revisiting the scheduling framework.
